文献速递糖尿病肥胖与代谢综合征

酮补充剂剂量依赖性降低2型糖尿病餐后血糖、血脂和胃饥饿素:随机交叉研究

Ketone supplementation dose-dependently lowers postprandial blood glucose, lipid and ghrelin levels in individuals with type 2 diabetes: a randomised crossover study.
PubMed 文献 · Diabetologia · 2025-11-28

两项随机参与者盲法交叉研究在丹麦奥胡斯大学医院开展,受试者为二甲双胍单药或单纯生活方式干预的2型糖尿病患者。研究1中14人餐前30分钟接受30g酮单酯(KE)、酮盐(KS)或安慰剂;研究2中10人在口服葡萄糖耐量试验(OGTT)前不同时间接受不同剂量KE。结果显示KE和KS分别使血糖增量AUC降低36%(95%CI 14,57)和22%(95%CI 1,44),并降低餐后NEFA和胃饥饿素,KE还降低甘油三酯且呈剂量依赖性降低血糖iAUC。

要点

  • 餐前补充酮单酯或酮盐可降低2型糖尿病患者餐后血糖、NEFA和胃饥饿素。
  • 酮单酯降低血糖增量AUC 36%(95%CI 14,57),酮盐降低22%(95%CI 1,44)。
  • 酮单酯呈剂量依赖性降低血糖iAUC,OGTT前30或60分钟摄入效果最强。

核心结论

  • 餐前酮补充剂降低2型糖尿病患者餐后血糖、脂质和胃饥饿素浓度,支持酮单酯补充在2型糖尿病管理中的治疗潜力。

研究设计与样本

  • 两项随机、参与者盲法交叉研究,在丹麦奥胡斯大学医院开展,受试者为二甲双胍单药或单纯生活方式干预的2型糖尿病患者。
  • 研究1:14名参与者分三次分别接受30g酮单酯、酮盐或安慰剂,于混合餐试验前30分钟摄入,主要结局为血糖增量AUC。
  • 研究2:10名参与者在六个不同场合,于OGTT前30分钟、60分钟或立即摄入不同剂量(0g、10g、20g、40g)酮单酯。

主要发现

  • 与安慰剂相比,酮单酯使血糖增量AUC降低36%(95%CI 14,57),酮盐降低22%(95%CI 1,44)。
  • 两种酮补充剂均降低餐后NEFA和胃饥饿素浓度,酮单酯还降低甘油三酯(n=14)。
  • 酮单酯剂量依赖性降低血糖增量AUC,OGTT前30分钟或60分钟摄入效果最强(n=10)。
  • 无严重不良事件,但报告了短暂轻度胃肠道症状,包括恶心和腹泻。

临床怎么用

  • 在2型糖尿病患者中,餐前30分钟或60分钟补充酮单酯可能有助于降低餐后血糖和脂质 excursions。
  • 需注意短暂轻度胃肠道症状(如恶心、腹泻),无严重不良事件报告。

局限性

  • 研究样本量较小(研究1 n=14,研究2 n=10)。
  • 受试者仅限二甲双胍单药或单纯生活方式干预的2型糖尿病患者。
  • 两项研究均在单一中心(丹麦奥胡斯大学医院)开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Postprandial hyperglycaemia and hyperlipidaemia are independent risk factors for CVD in individuals with type 2 diabetes. We aimed to test whether a ketone monoester (KE) and ketone salts (KS) reduce postprandial glucose and lipid excursions in individuals with type 2 diabetes. METHODS: In two randomised, participant-blind crossover studies we investigated individuals with type 2 diabetes treated with either metformin monotherapy or a lifestyle intervention alone. In study 1, 14 participants received 30 g of KE, KS or placebo 30 min before a mixed meal test on three separate occasions. The primary outcome was the incremental AUC (iAUC) for glucose. In study 2, ten participants were investigated on six separate occasions, consuming various doses (0 g, 10 g, 20 g and 40 g) of KE 30 min, 60 min or immediately before an OGTT. Both studies were conducted at Aarhus University Hospital, Denmark, with the primary investigator randomly assigning the intervention order. RESULTS: We found that the iAUC for glucose decreased by 36% (95% CI 14, 57) with KE and 22% (95% CI 1, 44) with KS compared with placebo. Both ketone supplements lowered postprandial NEFA and ghrelin concentrations, and KE reduced triglycerides (n=14). Furthermore, KE dose-dependently lowered the iAUC of glucose, with the strongest effect when ingested 30 min or 60 min before the OGTT (n=10). No serious adverse events occurred; however, transient mild gastrointestinal symptoms, including nausea and diarrhoea, were reported. CONCLUSIONS/INTERPRETATION: Pre-meal ketone supplementation reduced postprandial glucose, lipid and ghrelin concentrations. These findings support the therapeutic potential of KE supplementation in the management of type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT05263401 and NCT05581043 FUNDING: Novo Nordisk Foundation (NNF19OC0058872 and NNF22OC0081911), the Health Research Foundation of Central Denmark Region and the Aase Einar Danielsen Foundation (Jr. No. 23-10-0145).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bangshaab M, Bengtsen MB, Smedegaard S, et al. Ketone supplementation dose-dependently lowers postprandial blood glucose, lipid and ghrelin levels in individuals with type 2 diabetes: a randomised crossover study. Diabetologia. 2025. PMID: 41315088. doi:10.1007/s00125-025-06614-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。